Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

ARBs have 'modest benefits' on CV events

By Nigel Praities

Angiotensin receptor blockers confer a ‘modest benefit' over placebo in patients unable to tolerate ACE inhibitors, say researchers.

The results of the TRANSCEND study, presented at the European Society of Cardiology meeting in Munich this week, showed in 5,926 patients the ARB telmisartan reduced cardiovascular death, heart attack, stroke and hospitalisation for heart failure by 8%, compared with placebo.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say